Science News
from research organizations

Promising treatment for inherited form of kidney disease

Date:
November 4, 2012
Source:
Mayo Clinic
Summary:
A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease, researchers say.
Share:
         
Total shares:  
FULL STORY

A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD), Mayo Clinic researchers say. The medication, tolvaptan, slowed the pace of kidney cyst growth over the three years of the study.

The phase three clinical trial results were being presented November 3 at the American Society of Nephrology annual meeting and published online in the New England Journal of Medicine.

The multicenter study found tolvaptan demonstrated a nearly 50 percent reduction in the rate of increase in total kidney volume (a measurement of kidney cyst growth) in ADPKD patients over the study period, compared to placebo.

"ADPKD is the most common inherited and the fourth most common overall cause of kidney failure worldwide," says lead author Vicente Torres, M.D., Ph.D., Mayo Clinic nephrologist.

"In most patients with this disease, relentless cyst growth within the kidneys destroys the tissue, causes hypertension and painful complications, and negatively impacts the quality of life," Dr. Torres says. "The results of this study reveal a potential treatment that blunts kidney growth, lessens associated symptoms and slows kidney function decline when given over three years."

While the trial findings are encouraging, tolvaptan has not yet been approved for this indication, Dr. Torres notes.

The study was funded by Otsuka Pharmaceuticals.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John Ouyang, Frank S. Czerwiec. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. New England Journal of Medicine, 2012; 121103123025000 DOI: 10.1056/NEJMoa1205511

Cite This Page:

Mayo Clinic. "Promising treatment for inherited form of kidney disease." ScienceDaily. ScienceDaily, 4 November 2012. <www.sciencedaily.com/releases/2012/11/121104082203.htm>.
Mayo Clinic. (2012, November 4). Promising treatment for inherited form of kidney disease. ScienceDaily. Retrieved April 27, 2015 from www.sciencedaily.com/releases/2012/11/121104082203.htm
Mayo Clinic. "Promising treatment for inherited form of kidney disease." ScienceDaily. www.sciencedaily.com/releases/2012/11/121104082203.htm (accessed April 27, 2015).

Share This Page:


Health & Medicine News
April 27, 2015

Latest Headlines
updated 12:56 pm ET